Basiliximab/belatacept/mycophenolate-mofetil

Basiliximab/belatacept/mycophenolate-mofetil Reactions 1680, p65 - 2 Dec 2017 Basiliximab/belatacept/mycophenolate- mofetil Progressive multifocal leukoencephalopathy and the associated complications: case report An elderly man in his late 60s [exact age at the time of reaction onset not stated] developed progressive multifocal leukoencephalopathy (PML) and the associated complications including right hemiplegia, cortical blindness, coma and respiratory failure during treatment with basiliximab, belatacept and mycophenolate mofetil [not all routes, dosages and outcomes stated]. Eventually, he died of the PML and respiratory failure. The man, who had a history of immunoglobulin A nephropathy, had undergone deceased-donor kidney transplant in October 2013, at the age of 67-years. His immunosuppressive regimen included basiliximab induction with a maintenance therapy which included belatacept injection and mycophenolate mofetil. He received IV basiliximab 10 mg/kg on day 1 and 5, week 2, 4, 8 and 12. Beyond the third month, basiliximab was administered at a dose of 5 mg/kg/month. During the post-transplantation period, he had experienced multiple complications of viral reactivation for which he was concurrently treated with valganciclovir. He developed nephropathy of unspecified aetiology, due to which the dose of mycophenolate mofetil was reduced to 500mg twice daily. In June 2015, at 20 months post-transplantation, he was admitted due to left upper-limb weakness and visual disturbances. A month prior to the admission, he had the symptoms of mood disorders and confusion. He further developed symptoms of progressive right-sided hemiparesis with temporospatial disorientation. An MRI showed left frontoparietal sub-cortical white-matter lesions, without gadolinium enhancement, which suggested no vascular disease occurrence. These lesions were consistent with demyelination, suggestive of PML. Cerebrospinal (CSF) fluid analysis revealed a presence of John Cunningham virus (JCV) deoxyribonucleic acid, which confirmed the diagnosis of PML (JCV viral load of 7.15 × 10 copies/mL) that was considered to be related with basiliximab, belatacept and mycophenolate mofetil. The man’s mycophenolate mofetil therapy was discontinued. He had received the last injection of belatacept was administered two days prior to the admission. Due to the 2-week half life of belatacept, two plasma exchanges were performed for belatacept elimination. He received treatment with IV perfusion of polyclonal Igs [sic] for mild hypogammaglobulinaemia of unspecified aetiology. Thereafter, he developed complete right hemiplegia, cortical blindness and experienced no understanding towards the simple orders. His PML worsened and the he became bedridden. The JCV viral load in CSF increased to 1.67 × 10 copies/mL) on day 22. On day 33, his brain lesions deteriorated. He further received treatment with interleukin-7. However, his clinical neurological status worsened, with onset of coma on day 41. The JC virus viral load in CSF remained stable (1.45 × 10 copies/mL). After 69 days of the PML diagnosis, he died due to PML and respiratory failure. Author comment: "Progressive multifocal leukoencephalopathy (PML) is a deadly demyelinating disease due to central nervous system replication of the human polyomavirus JC virus (JCV) in immunosuppressed patients." Dekeyser M, et al. Refractory T-cell anergy and rapidly fatal progressive multifocal leukoencephalopathy after prolonged CTLA4 therapy. Open Forum Infectious Diseases 4: No. 2, 16 May 2017. Available from: URL: http:// doi.org/10.1093/ofid/ofx100 - France 803284771 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Basiliximab/belatacept/mycophenolate-mofetil

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/basiliximab-belatacept-mycophenolate-mofetil-fqp09EK3Cc
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38996-0
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial